[Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome]. 1986

K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga

This study was designed to evaluate the effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome (MDS). The subjects were 33 patients (19 acute myelocytic leukemia (AML), 9 MDS, 3 atypical leukemia and 2 unclassified leukemia). The age range was 19 to 84 years with a mean age of 51.5 years. We administered low-dose Ara-C (5-10 mg/m2/12 h s.c. or i.v.) for 13 to 35 days with a mean of 16.7 days. Complete remission and partial remission were obtained in 8 of 31 (25.8%) and in 9 of 31 (29.0%) respectively. A high response rate was found in M2 types showing a tendency for mature and refractory anemia with excess blasts in MDS according to the FAB classification. In our cases, severe pancytopenia in peripheral blood as a result of Ara-C was observed before normal hematopoiesis recurred. From the above results, the mechanism of low-dose Ara-C may induce remission by a cytotoxic rather than a differentiation effect. This treatment can be offered to patients with refractory, atypical leukemia and MDS with limited toxicity.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
April 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
April 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
December 1989, Bone marrow transplantation,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
January 1990, Leukemia research,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
October 1984, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
August 1985, Cancer,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
February 1986, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
February 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
September 1996, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Tsubaki, and A Horiuchi, and K Nagai, and A Kanamaru, and M Kohsaki, and T Kitani, and S Tagawa, and T Masaoka, and H Shibata, and K Yasunaga
January 1987, Haematologica,
Copied contents to your clipboard!